1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit
(
- Contribution to journal › Article
- 2023
-
Mark
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer : data from the randomized SBII:2 trial
(
- Contribution to journal › Article
- 2021
-
Mark
Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer
(
- Contribution to journal › Article
- 2020
-
Mark
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer : data from a randomised trial with long-term follow-up
(
- Contribution to journal › Article
- 2019
-
Mark
Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial
(
- Contribution to journal › Article
- 2017
-
Mark
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer : the Danish cohort of BIG 1-98
(
- Contribution to journal › Article
- 2010
-
Mark
17 beta-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer
(
- Contribution to journal › Article
- 2008
-
Mark
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
(
- Contribution to journal › Article
- 2005
-
Mark
ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis
(
- Contribution to journal › Article